Mexedrone
3-methoxy-4-methylmethcathinone
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Mexedrone is a synthetic stimulant of the substituted cathinone class. It is the alpha-methoxy derivative of mephedrone, markedly reduced in potency. Mexedrone is a weak non-selective monoamine reuptake inhibitor with faint serotonin-releasing activity, producing its effects by modestly elevating monoamine levels in the brain.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
mephedrone, other cathinones, dopamine-releasing stimulants +1 moremephedrone, other cathinones, dopamine-releasing stimulants, serotonergic stimulants show less
Mexedrone appeared on UK research chemical markets in August 2015, engineered to fall outside existing cathinone scheduling controls.[1] The UK Psychoactive Substances Act 2016 rendered it illegal after approximately nine months on the open market, and several other countries followed with specific scheduling. It remains primarily of forensic and toxicological interest, with no therapeutic applications proposed and minimal ongoing market presence.
Subjective effects include mild stimulation, mood elevation, and weak empathogenic warmth. The experience is subdued and diffuse — a faint serotonergic coloring over minimal dopaminergic drive, closer to a low-potency antidepressant-stimulant hybrid than a classical cathinone euphoriant.[1] Agitation, elevated heart rate, and anxiety are characteristic unsought effects.[2]
Mexedrone shows meaningful abuse potential in preclinical models but no documented physical dependence, and no lethal dose has been established.[3] The primary acute risks are cardiovascular and psychiatric — elevated heart rate and acute psychosis both emerged in confirmed hospital cases, even among patients with no prior psychiatric history.[2] Nearly all human data derive from polydrug contexts, and the compound's isolated risk profile remains poorly characterized.
History[edit]
Market emergence
Mexedrone entered the European research chemical market in August 2015, sold by UK internet retailers as a legal alternative to mephedrone.[1] Its design was strategic: introducing an alpha-methoxy group to the mephedrone scaffold produced a compound outside cathinone-specific drug controls while retaining some psychoactive activity. McLaughlin and colleagues noted the compound was "of particular interest to countries who operate generic drugs legislation".[1]
Scientific characterization
Two independent research efforts published the first scientific descriptions in 2016–2017: Qian and colleagues performed analytical characterization,[4] while McLaughlin and colleagues published the definitive pharmacological profile including crystal structure determination and monoamine transporter assays.[1] The crystal structure enabled unambiguous differentiation from the positional isomer N-methoxymephedrone — a compound with an identical molecular formula but dramatically different pharmacology.[1] Roberts and colleagues subsequently published the only clinically confirmed case series, identifying 11 patients with verified mexedrone exposure at City Hospital, Birmingham.[2]
Regulation and later research
Sweden scheduled mexedrone in January 2016, Japan followed in August 2016, and the UK Psychoactive Substances Act 2016 imposed a blanket ban from May 2016 — closing mexedrone's legal window after approximately nine months.[5] Preclinical abuse-potential studies did not appear until 2024, when Jeon and colleagues demonstrated conditioned place preference and self-administration in rodents[3] — data arriving nearly a decade after the compound first reached consumers.
Chemistry[edit]
Structural class
Mexedrone belongs to the substituted cathinone family within the broader phenethylamine class. It is the alpha-methoxy derivative of mephedrone: a methoxy group (–OCH₃) replaces the alpha-hydrogen on the mephedrone scaffold's beta-keto side chain. This single modification profoundly alters pharmacological activity, abolishing dopamine and norepinephrine releasing activity while retaining weak reuptake inhibitor.[1][6]
Mexedrone is a positional isomer of N-methoxymephedrone, which carries the methoxy group on the nitrogen rather than the alpha-carbon. Despite identical molecular formulae, these isomers display strikingly different pharmacology: N-methoxymephedrone is a fully effective releaser at all three monoamine transporters.[1]
Molecular properties
| Molecular formula | C₁₂H₁₇NO₂ |
| Molecular weight | 207.27 g/mol |
The molecular structure comprises a para-methylphenyl ring attached to a beta-keto side chain bearing alpha-methoxy and N-methyl substituents. The beta-keto group characteristic of all cathinones and the para-methyl ring substitution are shared with the parent compound mephedrone.
Stereochemistry
Mexedrone possesses a chirality center at C-2 (the alpha-carbon). The compound is typically characterized and sold as the racemate. No published enantiomer-specific pharmacological data exist.citation needed
Physical properties
Mexedrone presents as a white to colorless crystalline powder.[7] A full X-ray crystal structure has been determined,[1] enabling forensic differentiation from the positional isomer N-methoxymephedrone. Melting point, solubility, partition coefficient, and stability data remain uncharacterized in the accessible literature.
Pharmacology[edit]
Mechanism of action
Mexedrone acts as a weak non-selective monoamine reuptake inhibitor across the dopamine, norepinephrine, and serotonin transporters.[1] Unlike its parent compound mephedrone, mexedrone does not release dopamine or norepinephrine — it only blocks their reuptake. At the serotonin transporter alone, it displays weak releasing activity.[1]
This profile — reuptake inhibitor at all three transporters combined with serotonin-preferring releasing — distinguishes mexedrone from the multi-transporter releasing mechanism of mephedrone and partly explains its markedly attenuated potency. Roberts and colleagues independently confirmed dose-dependent inhibition of serotonin and dopamine reuptake.[2]
Mexedrone has been misclassified in some databases as a "dopamine releasing agent" and "norepinephrine releasing agent." This is incorrect. McLaughlin et al. (2017) demonstrated that mexedrone is devoid of releasing activity at DAT and NET.[1] Only weak serotonin-releasing activity was observed. Reuptake inhibitors and releasers produce different effect profiles, interaction risks, and abuse patterns.
Receptor targets
Beyond transporter interactions, mexedrone activates 5-HT₂A receptors — a selective antagonist fully reversed mexedrone-induced locomotor stimulation in mice.[3] Affinity for dopamine D₂ and broader 5-HT₂ receptor subtypes has also been reported,[2] though quantitative binding data are not available.
Pharmacokinetics
No controlled human pharmacokinetic studies have been published for mexedrone. Peak plasma concentration, oral bioavailability, plasma half-life, and urinary excretion remain uncharacterized in humans.
In vitro profiling using human liver microsomes identified three primary metabolic pathways: hydroxylation, N-dealkylation, and O-dealkylation.[8] CYP2C19 is the principal metabolizing enzyme — a notable difference from mephedrone, which relies primarily on CYP2D6.[9]
CYP2C19 is highly polymorphic. Poor metabolizers (2–3% of European populations, up to 15–20% of East Asian populations) may accumulate higher mexedrone plasma concentrations, increasing adverse effect risk.[8] A significant fraction of administered mexedrone is excreted unchanged.[8]
Mutagenicity
Mexedrone demonstrated direct mutagenic potential in laboratory cell cultures at concentrations of 35–100 µM, without requiring metabolic activation.[10] The mechanism does not involve oxidative stress.[10] Whether plasma concentrations achievable at recreational doses reach this range is unknown — no human pharmacokinetic data exist to contextualize the finding, and no in vivo studies have been conducted.
Neuroscience[edit]
Where it acts
Mexedrone engages the brain's dopaminergic mesolimbic pathway — the circuit running from the ventral tegmental area to the nucleus accumbens — though with substantially less strength than potent stimulants. Preclinical studies confirm it activates reward circuitry sufficiently to produce reinforcing behavior: mice developed place preference for mexedrone-associated environments, and rats self-administered the compound intravenous.[3] Neural activation markers concentrated in the dorsal striatum,[3] a pattern consistent with stimulant-class effects but suggesting a mixed monoaminergic mechanism.
Serotonergic modulation
The serotonergic component is central to mexedrone's character. Weak serotonin-releasing activity drives extracellular serotonin elevation,[1] and acute dosing reduced SERT protein levels in the dorsal striatum[3] — indicating the brain begins adapting to sustained serotonergic stimulation after a single exposure. The 5-HT₂A receptor is a necessary component of at least the locomotor effects, as demonstrated by complete reversal with a selective antagonist.[3]
Several fundamental questions remain unanswered. Whether mexedrone produces lasting changes to brain structure or serotonergic function with repeated use is unknown — the acute serotonin transporter downregulation observed after a single dose[3] raises this possibility but has not been studied longitudinally.
Subjective Effects[edit]
Mexedrone delivers a muted stimulant experience in which serotonergic warmth predominates over dopaminergic push. The pharmacological signal is weak enough that set, setting, and expectation can dominate the subjective picture — what a user brings to the experience may shape it more than the compound itself. Across the dose range, the shift is one of degree rather than kind: low doses produce barely perceptible mood lift, while higher doses amplify stimulation and introduce mild empathogenic warmth without approaching classical cathinone intensity.
Relative to mephedrone, mexedrone is markedly less euphoriant, less stimulating, and less entactogenic — consistent with the loss of dopamine and norepinephrine releasing activity.[1] Where mephedrone sits between MDMA and amphetamine in experiential character, mexedrone occupies a distinctly lower register, closer to a low-potency SSRI-stimulant hybrid.
Effect Grid
Moderate stimulation with noticeable euphoria, though mild compared to mephedrone due to the absence of DAT/NET releasing activity. Spontaneous body sensations and touch enhancement become apparent. Thought acceleration and thought connectivity may occur. A serotonergic coloring — subtle sociability enhancement and faint entactogenic warmth — distinguishes the experience from purely dopaminergic stimulants.
Bruxism, wakefulness, and appetite suppression are likely. Some users report excessive sweating and dehydration sensation. Abnormal heartbeat (tachycardia) becomes a possibility at this tier.
The comedown phase commonly includes cognitive fatigue, mild irritability, and transient low mood. Insomnia is likely if dosed within 6 hours of intended sleep.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Pupil dilation · Body high · Dry mouth · Heart rate perception changes · Physical fatigue · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Insomnia · Muscle tension · Restlessness · Spontaneous body sensations · Sexual arousal enhancement · Tingling / electric sensations · Dizziness · Headache · Nausea · Trembling
Physical fatigue · Tactile euphoria · Bruxism · Dehydration sensation · Excessive sweating · Insomnia · Muscle tension · Restlessness · Spontaneous body sensations · Sexual arousal enhancement · Tingling / electric sensations · Dizziness · Headache · Nausea · Trembling
Openness enhancement · Motivation enhancement · Aesthetic enhancement · Focus enhancement · Information processing enhancement · Introspection enhancement · Analysis enhancement · Creativity enhancement · Humor enhancement
Information processing enhancement · Introspection enhancement · Analysis enhancement · Creativity enhancement · Humor enhancement
Anxiety · Emotional enhancement · Irritability · Anxiety suppression · Dysphoria · Emotional lability
Dysphoria · Emotional lability
Social connection · Trust enhancement · Communication enhancement · Sociability enhancement
Timeline
Initial awareness of mild stimulation and faint body sensations. Effects are sub-threshold for most — a gentle shift in baseline alertness rather than a distinct onset.
Building stimulation and mood elevation. Body high begins to emerge alongside subtle sociability enhancement. Wakefulness becomes noticeable.
Maximum stimulation, mild euphoria, touch enhancement, and serotonergic warmth. Thought acceleration and spontaneous body sensations are at their height. Tachycardia most likely during this phase.
Gradual decline in stimulation and euphoria. Cognitive fatigue and irritability may emerge as monoamine levels normalize. Appetite begins to return.
Residual fatigue and possible low mood. Difficulty sleeping may persist. Mild cognitive impairment and reduced motivation are common.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- mephedrone · other cathinones · dopamine-releasing stimulants
Toxicity
Acute toxicity
No lethal dose has been established for mexedrone in any species.safety citation needed The only analytically confirmed human data come from 11 hospital cases in Birmingham, UK.[2] Agitation was the dominant feature (10 of 11 cases), with six patients requiring sedation or physical restraint. All patients recovered; no deaths occurred in this series. Median hospital stay was 20 hours.
Mexedrone has been detected in blood samples from fatal mixed-substance poisonings,[11] but all fatalities involved multiple substances and organ failure. No death has been attributed solely to mexedrone in published literature.
Cardiovascular toxicity
Elevated heart rate is the most consistently documented cardiovascular effect, occurring in 7 of 11 confirmed cases (64%).[2] As a sympathomimetic stimulant, mexedrone is expected to raise heart rate and blood pressure in a dose-dependent manner. More severe cardiovascular complications — dangerous blood pressure spikes, irregular heartbeat, reduced blood supply to the heart — are characteristic of the broader cathinone class[12] but have not been specifically documented for mexedrone alone.
Mutagenicity
Mexedrone showed direct mutagenic potential in laboratory cell cultures at concentrations of 35–100 µM.[10] Whether recreational doses produce plasma concentrations in this range is unknown — no human pharmacokinetic data exist, and no in vivo studies have been conducted.
Psychological risks
Acute psychosis occurred in 3 of 11 confirmed cases (27%), presenting as hallucinations and delusions with paranoid content.[2] None of these patients had prior psychiatric history. Whether these episodes were attributable to mexedrone alone or to polydrug combinations is uncertain.
Anxiety, nervousness, and paranoia are reported across the cathinone class.[13] Mexedrone's weaker potency relative to mephedrone may reduce but does not eliminate psychotomimetic risk, particularly at higher doses or with repeated use. No data exist on long-term psychiatric consequences.
Tolerance and dependence
Preclinical evidence demonstrates meaningful abuse potential: mice developed dose-dependent place preference, rats self-administered the compound, and mexedrone fully substituted for cocaine in discrimination paradigms.[3] Acute administration produced SERT downregulation,[3] suggesting neuroadaptive changes that may underlie tolerance to serotonergic effects.
Community reports suggest tolerance develops with repeated use, with an estimated reset period of approximately 1.5 weeks. Cross-tolerance with other stimulants is reported.inferred
No published human data characterize physical dependence, withdrawal, or compulsive use patterns specific to mexedrone. The moderate dependence potential attributed to the compound is consistent with preclinical evidence[3] and cathinone-class data but remains unvalidated in humans.
Drug interactions
Mexedrone's serotonin reuptake inhibitor combined with weak serotonin-releasing activity creates interaction risk with any co-administered serotonergic compound. CYP2C19-dependent metabolism adds a pharmacokinetic dimension.
Serotonergic interactions: Combining mexedrone with other serotonergic agents risks precipitating serotonin syndrome — a potentially fatal condition involving muscle rigidity, dangerously elevated body temperature, and cardiovascular instability.
- Tramadol: Inhibits serotonin reuptake and carries seizure risk through serotonergic mechanisms.[14][15] Combined with mexedrone, the serotonergic burden creates risk of severe serotonin syndrome.[14]safety citation needed
- MDMA: Produces massive serotonin release; combined with mexedrone, creates additive serotonergic toxicity and dangerously elevated body temperature.[16]
- MAOIs: Prevent monoamine breakdown; combined with mexedrone's serotonin activity, risk of dangerously high blood pressure and severe serotonin syndrome.[12]safety citation needed
- SSRIs/SNRIs: Additive serotonergic activity creates dose-dependent serotonin syndrome risk.[17]
Pharmacokinetic interactions: CYP2C19 inhibitors (omeprazole, fluoxetine, fluvoxamine) may substantially increase mexedrone plasma concentrations by impairing metabolic clearance.[8] Fluoxetine is both a CYP2C19 inhibitor and an SSRI, creating a dual pharmacokinetic-pharmacodynamic interaction.
Stimulant-alcohol combination: Stimulants combined with alcohol mask signs of alcohol intoxication, increase cardiac strain, and promote dehydration.[17]
Contraindications
Heart conditions: Mexedrone produces sympathomimetic stimulation (elevated heart rate in 64% of clinical presentations).[2] Pre-existing high blood pressure, irregular heartbeat, coronary artery disease, or structural heart defects represent absolute contraindications.[12]
Psychiatric vulnerability: Acute psychosis occurred in 27% of confirmed cases, in patients without prior psychiatric history.[2] Personal or family history of psychotic disorders, bipolar disorder, or schizophrenia spectrum conditions represents a strong contraindication.
Concurrent serotonergic medication: Any person taking SSRIs, SNRIs, MAOIs, tramadol, or other serotonergic agents faces additive serotonin toxicity risk — absolute contraindication for MAOI users, strong contraindication for SSRI/SNRI users.[17]
CYP2C19 poor metabolizer status: Individuals who are CYP2C19 poor metabolizers (2–3% of European ancestry, up to 15–23% of East Asian ancestry) may experience elevated plasma concentrations and increased adverse effects at standard doses.[8]
Pregnancy and lactation: No reproductive or developmental toxicity data exist. Exposure during pregnancy or lactation is contraindicated.safety citation needed
Liver or kidney impairment: Mexedrone metabolism depends on liver enzymes; impaired liver or kidney function may reduce clearance.safety citation needed
Harm Reduction[edit]
Forms & Identification
Mexedrone typically circulates as a white crystalline powder. Because it was designed as a legal alternative to mephedrone, samples may contain the synthesis by-product alpha-chloromethylmephedrone[1] or be confused with the positional isomer N-methoxymephedrone — a compound with an identical molecular formula but dramatically different pharmacological activity.[1] Standard reagent kits can help distinguish mexedrone from unrelated substances but cannot reliably differentiate it from close structural relatives. Quantitative analytical testing is the only reliable way to confirm identity and purity.
Guidelines
- Test all material with reagent kits before use — mexedrone cannot be visually distinguished from more potent cathinones or its own positional isomers.
- Start with a low dose and wait for full onset before redosing. Oral is the only route with any documentation; alternative routes are entirely uncharacterized.
- Stay hydrated but avoid overhydration — moderate water intake, not excessive.
- Ensure adequate sleep, food, and hydration before use.
- Have a sober companion present, particularly for first-time use.
- Do not drive or operate machinery.
Set & Setting
Mexedrone's pharmacological effects are weak enough that context heavily shapes the experience. A calm, familiar environment with trusted companions is more likely to produce the mild sociability and warmth the compound can offer, while stressful or chaotic settings may amplify the agitation that dominates clinical presentations.[2] Avoid use when anxious, sleep-deprived, or in unfamiliar surroundings.
Aftercare & integration. The comedown from mexedrone is generally mild but may include low mood, fatigue, and irritability — consistent with temporary monoamine depletion. Prioritize sleep, nutritious food, and hydration in the 24–48 hours following use. Avoid redosing to chase fading effects, as this extends the recovery period without meaningfully improving the experience. If anxiety, paranoia, or perceptual disturbances persist beyond 48 hours, consult a medical professional.
Recovery & Support
While mexedrone's abuse potential is lower than that of more potent cathinones, compulsive redosing patterns can develop with any stimulant. If use has become frequent, difficult to control, or is causing problems in daily life, professional support is available. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential referrals. Online communities and harm reduction organizations can offer peer support and evidence-based resources.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Seek immediate medical help if any of the following occur: chest pain or pressure, seizure, loss of consciousness, body temperature that feels dangerously hot to the touch, hallucinations or delusions, severe agitation that cannot be managed with reassurance, or inability to maintain awareness of surroundings.
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a quiet, cool environment.
- 3. Do not restrain unless there is immediate danger to self or others.
- 4. Monitor breathing and heart rate while waiting for help.
- 5. Do not induce vomiting.
What to tell the dispatcher: Name the substance (mexedrone, a synthetic cathinone), approximate amount taken, time of ingestion, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Mexedrone's legal status varies by jurisdiction. It was initially sold legally in the United Kingdom during a narrow window between its market appearance in August 2015 and the enactment of the Psychoactive Substances Act 2016 in May 2016. Several countries have subsequently scheduled mexedrone specifically or captured it under blanket psychoactive substance bans. In many jurisdictions, its legal status remains ambiguous or unaddressed by specific legislation.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Illegal (Psychoactive Substances Act 2016) | Blanket ban on all psychoactive substances not specifically exempted; effective 26 May 2016[5] |
| Sweden | Controlled substance | Scheduled 26 January 2016[5] |
| Japan | Controlled substance | Scheduled 24 August 2016[5] |
| United States | Not specifically scheduled | No explicit DEA scheduling identified. The Federal Analogue Act may apply as mexedrone is a structural analog of Schedule I mephedrone, but no confirmed legal determination or case law has been identifiedcitation needed |
| European Union | Varies by member state | No formal EMCDDA risk assessment identified. Individual member states may schedule independentlycitation needed |
| Australia | Unknown | No published data on scheduling status identifiedcitation needed |
| Canada | Unknown | No published data on scheduling status identifiedcitation needed |
Analogue act considerations
In the United States, mexedrone's status under the Federal Analogue Act depends on whether it is deemed "substantially similar" in structure and pharmacological effect to a Schedule I or II controlled substance — in this case, mephedrone. The act applies only when the substance is intended for human consumption. No published legal analysis, DEA emergency scheduling order, or court case specifically addressing mexedrone has been identified. Users and researchers in the United States should assume potential federal analogue liability in contexts involving human consumption.
references
- [1] ^abcdefghijklmnopqMcLaughlin G, Morris N, Kavanagh PV, Power JD, Dowling G, Twamley B, O'Brien J, Talbot B, Walther D, Partilla JS, Baumann MH, Brandt SD (2017) Synthesis, characterization and monoamine transporter activity of the new psychoactive substance mexedrone and its N-methoxy positional isomer, N-methoxymephedrone — Drug Testing and Analysis doi:10.1002/dta.2053
- [2]
- [3]
- [4] ^Qian Z, Jia W, Li T, Liu C, Hua Z (2017) Identification and analytical characterization of four synthetic cathinone derivatives iso-4-BMC, beta-TH-naphyrone, mexedrone, and 4-MDMC — Drug Testing and Analysis doi:10.1002/dta.1983
- [5]
- [6] ^Nadal-Gratacós N, Pazos MD, Pubill D, Camarasa J, Escubedo E, Berzosa X, López-Arnau R (2024) Structure-Activity Relationship of Synthetic Cathinones: An Updated Review — ACS Pharmacology and Translational Science doi:10.1021/acsptsci.4c00299